Dermira (NASDAQ:DERM)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Wednesday, AnalystRatings.com reports.
The analysts wrote, “Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.””
DERM has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Dermira from a “hold” rating to a “sell” rating in a report on Thursday, March 21st. Raymond James raised shares of Dermira from an “underperform” rating to a “market perform” rating and set a $6.71 target price for the company in a report on Thursday, January 17th. BidaskClub raised shares of Dermira from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Finally, Svb Leerink initiated coverage on shares of Dermira in a research report on Friday, February 22nd. They set an “outperform” rating and a $20.00 price target on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. Dermira has a consensus rating of “Buy” and an average price target of $18.30.
Dermira (NASDAQ:DERM) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.39). The company had revenue of $2.45 million during the quarter, compared to analyst estimates of $2.63 million. Dermira had a negative net margin of 523.25% and a negative return on equity of 309.23%. On average, sell-side analysts expect that Dermira will post -4.8 EPS for the current year.
In other news, insider Eugene A. Bauer sold 35,000 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $15.00, for a total transaction of $525,000.00. Following the completion of the sale, the insider now owns 43,900 shares of the company’s stock, valued at approximately $658,500. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 14.80% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Advisor Group Inc. lifted its holdings in shares of Dermira by 117.0% during the 1st quarter. Advisor Group Inc. now owns 6,062 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 3,269 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in shares of Dermira by 48,273.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 7,241 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Dermira by 2,500.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 10,400 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 10,000 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of Dermira during the 3rd quarter worth approximately $128,000. Finally, Metropolitan Life Insurance Co. NY lifted its holdings in shares of Dermira by 356.7% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,912 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 10,085 shares during the period. 68.00% of the stock is owned by institutional investors.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Featured Story: How to interpret the current ratio
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.